Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CASP1 | P29466 | 1/20 | 0.68 |
| ▸ | CASP7 | P55210 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8666334 | 0.98 | POLB (0.68) | POLBALDH1A1HSD17B10CYP3A4CASP1 | |
| Iodoacetamide SCHEMBL8666075 | 0.89 | POLB (0.57) | POLBALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL8664913 | 0.87 | POLB (0.75) | POLBALDH1A1HSD17B10CYP3A4CASP1 | |
| Hydrochloric Acid SCHEMBL8668067 | 0.86 | POLB (0.73) | POLBALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL515773 | 0.85 | POLB (0.77) | POLBALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL8595449 | 0.84 | POLB (0.71) | POLBALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL28991327 | 0.83 | ALDH1A1 (0.72) | POLBALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL3368846 | 0.83 | POLB (0.69) | POLBALDH1A1HSD17B10CYP3A4CASP1 | |
| Hydrochloric Acid SCHEMBL6496307 | 0.83 | POLB (0.69) | POLBALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL8667688 | 0.83 | ALDH1A1 (0.70) | POLBALDH1A1HSD17B10CYP3A4CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202821-A1 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
| WO-2020205646-A2 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-08 | — | — | WO | disclosed |
| US-5843634-A | Genetically engineered enzymes and their conjugates for diagnostic assays | ABBOTT LABORATORIES (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0688364-A4 | GENETICALLY ENGINEERED ENZYMES AND THEIR CONJUGATES FOR DIAGNOSTIC ASSAYS | ABBOTT LAB (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5516647-A | 6-PHENYL-IMIDAZO(2,1-B)THIAZOLES | ABBOTT LABORATORIES (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0688364-A1 | GENETICALLY ENGINEERED ENZYMES AND THEIR CONJUGATES FOR DIAGNOSTIC ASSAYS | ABBOTT LABORATORIES (US) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994020636-A9 | GENETICALLY ENGINEERED ENZYMES AND THEIR CONJUGATES FOR DIAGNOSTIC ASSAYS | — | 1994-11-24 | — | — | WO | disclosed |
| WO-1994020636-A1 | GENETICALLY ENGINEERED ENZYMES AND THEIR CONJUGATES FOR DIAGNOSTIC ASSAYS | ABBOTT LABORATORIES (US) | 1994-09-15 | — | — | WO | disclosed |
| US-5097097-A | Tracers, medical diagnosis | ABBOTT LABORATORIES (US) | 1992-03-17 | — | — | US | disclosed |
| US-4593089-A | Determining aminoglycosides | ABBOTT LABORATORIES (US) | 1986-06-03 | — | — | US | disclosed |
| US-4420568-A | DETERMINING LIGANDS IN SAMPLE | ABBOTT LABORATORIES (US) | 1983-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202821-A1 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | PARG, PARP15, PLG | POLB 1840/4885ALDH1A1 4146/4885HSD17B10 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.